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PENYEDIAAN DAN PENILAIAN PENYEBARAN PEPEJAL 
FENOFIBRAT-GELUCIRE 44/14 
 
ABSTRAK 
 
Potensi formulasi berasaskan sebaran pepejal menggunapakai Gelucire 44/14 
sebagai pembawa untuk meningkatkan pelarutan serta biokeperolehan oral 
fenofibrat, sejenis drug yang tak mudah larut, telah disiasat. Penyebaran 
pepejal dengan nisbah drug-pembawa yang berbeza disediakan dengan 
menggunakan kaedah cantuman konvensional dan dicirikan menggunakan 
analisis terma, mikroskopi optik dan ujian pelarutan. Keputusan ujian pelarutan 
ini dibandingkan dengan keputusan dua lagi fenofibrat, iaitu serbuk drug itu 
bersaiz mikron dan tablet komersial yang mempunyai biokeperolehan supra. 
Tiada peningkatan ketara dalam pelarutan drug melebihi kadar pelarutan 
fenofibrat bersaiz mikron diperolehi dari pepejal penyebaran yang disediakan.  
Pengurangan dalam pelarutan drug tersebut boleh disabitkan kepada kehadiran 
hablur-hablur drug yang besar yang terbentuk semasa penyediaan penyebaran 
pepejal tersebut. Namun begitu, setelah pengubahsuaian dilakukan ke atas 
kondisi-kondisi penyediaan, dengan menambahkan drug pada suhu yang 
rendah secara relatif dan dengan penambahan polietilin glikol (PEG) 400 untuk 
merendahkan takat lebur matriks, mengakibatkan pemerolehan hablur drug 
yang lebih kecil serta penghakisan matriks yang lebih cepat. Akibatnya, 
pelarutan lengkap dicapai setelah kira-kira 60 minit ujian berbanding pelarutan 
sebanyak 65% untuk serbuk drug yang bersaiz mikron. Penilaian in vivo 
penyebaran pepejal fenofibrat-Gelucire 44/14 yang mengandungi polietilin glikol 
(PEG) 400 menunjukkan  bahawa  takat  serapan drug, seperti yang dinyatakan 
 
xiv
oleh AUC0-, dipertingkatkan sebanyak kira-kira 60% berbanding dengan takat 
serapan fenofibrat yang bersaiz mikron. Berdasarkan keputusan kajian ini, 
dapat disimpulkan bahawa apabila kaedah cantuman konvensional gagal 
mengurangkan saiz partikel drug, teknik penambahan partikel drug yang 
bersaiz ke dalam matriks pada suhu yang rendah harus dipertimbangkan. Hasil 
kajian juga menyarankan bahawa penurunan takat lebur matriks boleh 
meningkatkan kadar  pelarutan.   
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PREPARATION AND EVALUATION OF FENOFIBRATE-GELUCIRE 44/14 
SOLID DISPERSIONS 
 
ABSTRACT 
 
The potential of solid dispersion-based formulation using Gelucire 44/14 as a 
carrier to enhance the dissolution and oral bioavailability of fenofibrate, a poorly 
water-soluble drug, was investigated. Solid dispersions with different drug-to-
carrier ratios were prepared by the conventional fusion method and 
characterized using thermal analysis, optical microscopy and dissolution testing. 
The dissolution results were compared with those of two fenofibrate 
formulations; the micronized drug powder and commercial tablet having 
suprabioavailability. No substantial increase in the drug dissolution, over that of 
micronized fenofibrate, could be obtained from prepared solid dispersions. 
Decreased drug dissolution was attributed to the presence of large drug crystals 
formed during the preparation of the solid dispersions. However, modifying the 
preparation conditions, by adding the drug to the carrier at a relatively low 
temperature, and incorporating polyethylene glycol (PEG) 400 to lower the 
melting point of the matrix, resulted in much smaller drug crystals and rapidly 
eroding matrices being obtained. Consequently, complete drug dissolution was 
achieved after approximately 60 minutes of the test, compared with 65% 
dissolution for micronized drug powder. In vivo evaluation of fenofibrate-Gelucire 
44/14 solid dispersion containing polyethylene glycol (PEG) 400 showed that the 
extent of drug absorption, expressed as AUC0-, was increased by 
approximately 60% over that of micronized fenofibrate. On the basis of the 
 
xvi
results of this study, it was concluded that when the conventional fusion method 
fails to reduce the drug particle size, the technique of incorporating drug 
microparticles into the matrix at lower temperatures is worth considering. The 
findings also suggest that lowering the melting point of the matrix can increase 
the dissolution rate. 
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CHAPTER 1. INTRODUCTION 
 
Drug absorption from solid oral dosage forms depends on the release of the 
drug substance from the delivery system, the dissolution of the drug under the 
physiological conditions and the drug permeability across the gastrointestinal 
tract (Ansari et al.,2004). Poorly water-soluble drugs are expected to have 
dissolution-limited absorption. Increasing the drug solubility may substantially 
contribute to improved drug absorption, and consequently, drug bioavailability. 
Solid dispersion techniques have been used to enhance the dissolution and oral 
bioavailability of many poorly soluble drugs (Habib, 2000). 
 
1.1   Solid dispersions 
1.1.1   Historical background 
The work of Sekiguchi and Obi (1961) was the first to show the possibility of 
increasing oral absorption of a drug incorporated into a ‘eutectic mixture’. 
Sulfathiazole in a ‘eutectic mixture’ with urea showed higher oral absorption and 
excretion than ordinary sulfathiazole. The term ‘solid-in-solid solutions’ was first 
used by Levy (1963) and Kanig (1964) who indicated that many drugs could form 
‘solid-solid solutions’ with mannitol. Later, Chiou and Niazi (1971) reported that 
sulfathiazole-urea fused mixtures, at specific concentrations, formed ‘solid 
solutions’ or ‘amorphous precipitations’, in which the dissolution rate of 
sulfathiazole was increased significantly. Furthermore, ‘glassy solutions’ were 
obtained after cooling the melts of 5 and 20% of griseofulvin in citric acid, and 
again, the dissolution rate of the drug was increased (Chiou & Riegelman, 1969). 
Finally, Chiou and Riegelman (1971a) brought together all the previous terms and 
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classified them into categories under the term ‘solid dispersions’.   
 
1.1.2   Definition of solid dispersions 
According to Chiou and Riegelman (1971a), a solid dispersion is "the dispersion 
of one or more active ingredients in an inert carrier at solid-state prepared by 
melting (fusion), solvent or the melting-solvent method". The carrier used has 
traditionally been a water-soluble or water-miscible polymer such as polyethylene 
glycol (PEG) or polyvinylpyrrolidone (PVP) or low molecular weight materials 
such as urea, citric acid and mannitol. However, the proliferation of publications in 
the solid dispersions area has led to a broadening of these definitions to include 
water-insoluble matrices such as Gelucires (Craig, 2002). Table 1.1 shows 
different materials used as carriers for solid dispersions. 
 
1.1.3   Methods of preparing solid dispersions 
1.1.3(a)   Melting or fusion method 
In this method, a physical mixture of the drug and the carrier is heated until it is 
melted. The melt is then cooled, and the resultant solid dispersion is pulverized 
and sieved (Sekiguchi & Obi, 1961).  
 
The question of whether the drug needs to be dissolved in the molten carrier or 
not has not been fully resolved (Craig, 2002). Indeed, Craig and Newton (1991) 
used a low temperature fusion method to prepare solid dispersions; they added 
the drug to the   molten  carrier  at  a  relatively  low  temperature.  By  using  this  
method,  the  structure  of  the  drug  particles  remains  largely  unchanged 
during the manufacturing process. 
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   Table 1.1 Different materials used as carriers for solid dispersions 
               (Vadnere, 2002) 
 
 
 
 
 
Sugars 
  Dextrose, 
Sucrose, 
Galactose, 
Sorbitol, 
Maltose, 
Xylitol, 
Mannitol, 
Lactose 
Acids 
 
 Citric acid, 
Succinic acid 
 
 
 
 
Polymeric 
materials 
 
 
 
 
Polyvinylpyrrolidone (PVP), 
Polyethylene glycols (PEG), 
Hydroxypropyl-methylcellulose, 
Methylcellulose, 
Hydroxyethylcellulose, 
Hydroxypropylcellulose, 
Cyclodextrins, 
Pectin, 
Galactomannan 
 
Insoluble or 
enteric polymers 
  Hydroxypropylmethylcellulosephthalate, 
Eudragit L-100, 
Eudragit S-100, 
Eudragit RL, 
Eudragit RS 
Sur 
 
Surfactants 
 
  Polyoxyethylene stearate, 
Poloxamer 188, 
Deoxycholic acid, 
Tweens, 
Spans 
 
    
Miscellaneous 
 
 
  Pentaerythritol, 
  Pentaerythrityltetracetate, 
Urea, 
Urethane, 
Hydroxyalkylxanthins 
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Nevertheless, the cooling rate used may significantly affect the aging behavior 
of the solid dispersions. It has been reported that the crystallinity of drug in solid 
dispersions is less affected by aging when a slow cooling rate is used because 
thermodynamically more stable systems are produced (Duclos et al., 1990; 
Saers et al., 1993; Serajuddin, 1999). On the other hand, rapid cooling of 
molten mixtures is desirable because it leads to instantaneous solidification, 
resulting in the drug molecules being trapped in the carrier matrix (Chiou & 
Riegelman, 1971a). For rapid cooling, Sekiguchi and Obi (1961) used ice bath 
with vigorous stirring, Goldberg et al. (1966) poured the fused mixture onto 
ferrite plate. On the other hand, Chiou and Riegelman (1969) used stainless 
steel plates cooled by  flowing air or  water on the opposite side of the plate. 
However, a solid mass was formed after cooling the molten mixture, so it was 
necessary to pulverize the solidified mixture before it could be tested. To avoid 
the pulverization process which would change the physical structure of solid 
dispersions, Kanig (1964) used the spray congealing technique. By using this 
technique, solid dispersions in pellet form were obtained.  
 
Direct filling of molten mixtures into hard gelatin capsules was first reported by 
Francois and Jones in 1978. Using this method for preparing solid dispersions 
was described later by Chatham in 1987. Subsequently, an automatic capsule 
filling machine was adapted to fill liquids instead of powders. Using this 
approach, pulverization and its potential negative effects on the structure of 
solid dispersions could be avoided. 
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1.1.3(b)   Solvent method 
This method includes dissolving the drug and the carrier in a common organic 
solvent, followed by evaporating the solvent at elevated temperature, under 
vacuum, or by freeze-drying or spray-drying the mixture (Serajuddin 1999). 
Tachibana and Nakamura (1965) used this method to prepare a solid dispersion 
of beta-carotene in polyvinylpyrrolidone (PVP) by using chloroform as a 
cosolvent. 
 
1.1.3(c)   Melting-solvent method 
In this method, the drug is dissolved in a  minimum amount of an organic 
solvent, and then it is added to the molten carrier. Chiou and Riegelman 
(1971a) used this method to prepare spironolactone-polyethylene glycol 6000 
solid dispersion without removing the solvent. They  reported that 5-10% (w/w) 
of liquid compound could be incorporated into polyethylene glycol 6000  without 
significant loss of its solid property. 
 
1.1.3(d)   Hot-melt extrusion 
In this technique, the blend of drug and carrier is processed with a twin-screw 
extruder of the same type used in the polymer industry. The blend is 
simultaneously melted, homogenized and then extruded and shaped as tablets, 
granules, pellets, sheets, sticks or powder. An important advantage of the hot 
melt extrusion method is that the drug-carrier mixture is only subjected to 
elevated temperatures for a few minutes, which enables both the drug and the 
carrier to remain thermally stable (Zhu, 2002). 
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1.1.3(e)   Supercritical fluid process 
This process includes dissolving the drug and carrier in supercritical CO2 under 
precise conditions of temperature and pressure, followed by rapid 
depressurization. Supercritical CO2 is nontoxic and it has the potential as an 
alternative for organic solvents (Vadnere, 2002).  
 
1.1.4   Classification of solid dispersions 
1.1.4(a)   Simple eutectic mixture 
Simple eutectic mixture can be obtained from the rapid solidification of the fused 
liquid of two components that show complete liquid miscibility and negligible 
solidsolid solubility. Upon cooling, the molten mixture forms a microfine 
dispersion of the two components with a concomitant decrease in the melting 
points of the two components (Chiou & Riegelman, 1971a; Craig, 2002). It was 
reported that chloramphenicol and paracetamol formed eutectic mixtures with 
urea (Sekiguchi  et al. , 1964; Goldberg et al.,1966). 
 
1.1.4(b)   Solid solution 
In this class, the drug and the carrier crystallize together in a homogeneous one-
phase system, and the particle size of the drug is reduced to its molecular size  
(Chiou & Regielman,1971a). In other words, the dissolution of the drug in the 
carrier occurs in the solid state. Hence, this system would be expected to yield 
much higher rates of dissolution than simple eutectic systems. Examples include 
digitoxin, hydrocortisone acetate and prednisolone dispersions in polyethylene 
glycol 6000 (PEG 6000) (Chiou & Riegelman, 1971b). In practice, the occurrence 
of solid solubility of less than 2% is considered insignificant (Habib, 2000).  
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1.1.4(c)   Amorphous precipitation in a crystalline carrier 
The active ingredient in some solid dispersions may precipitate out as an 
amorphous deposit in the crystalline carrier, such as the dispersion of sulfathiazole 
in urea (Chiou & Riegelman, 1971a; Ford, 1986). In amorphous materials, 
molecules are randomly arranged, in contrast to crystalline materials where the 
molecules are arranged in an ordered three-dimensional array (Martin et al., 1993). 
 
1.1.4(d)   Glassy solutions or suspensions 
Amorphous polymers, such as polyvinylpyrrolidone (PVP), can form glassy 
systems in which the drug is dispersed either as molecules or as particles (Craig, 
2002). The glassy material is characterized by transparency and brittleness below 
the glass transition temperature, and the lattice energy of a glass solution is less 
than that of a solid solution. On heating, a glassy material softens progressively 
and continuously without a sharp melting point. Taylor and Zografi (1997) reported 
that indomethacin and polyvinylpyrrolidone (PVP) formed a glass solution. 
 
1.1.4(e)   Compound or complex formation 
This system is characterized by complexation of two components in a binary 
system during solid dispersion preparation. For example, it was reported that 
digoxin and hydroquinone formed a complex which exhibited a high dissolution 
rate (Bochner et al., 1977). 
 
1.1.5   Characterization of solid dispersions 
Several methods have been used to characterize solid dispersions, such as 
differential scanning calorimetry (DSC), X-ray diffraction (XRD), infrared 
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spectroscopy (IR), hot stage and electron microscopy, and dissolution testing. 
Among these, thermal and spectral methods (i.e. DSC, XRD and IR) are of 
special interest. The main purpose of using these methods is to differentiate 
between crystalline and non-crystalline structure of solid dispersions. 
  
1.1.5(a)   Differential scanning calorimetry 
When a material is heated or cooled, there is a change in its structure (e.g. 
melting or crystallization), or its composition (e.g. oxidation). These changes are 
connected with heat exchange. Some of these changes are endothermic (i.e. 
heat consuming process such as melting), and others are exothermic (i.e. heat 
producing process such as crystallization) (Clas et al., 2002). Differential 
scanning calorimetry (DSC) is used for measuring the differences in heat flow 
between a sample and a reference during a controlled change of temperature. 
DSC analysis allows quantitative and qualitative information to be obtained about 
the physical and chemical changes that occur in the sample. DSC is used 
extensively in pharmaceutical industry to determine the melting points, purity, and 
glass transition temperatures of materials (Souillac & Rytting, 1999). In the solid 
dispersion area, DSC is a powerful tool in evaluating the drug-carrier interactions, 
determining the solubility of a drug in a polymeric carrier, detecting polymorphic 
modifications and examining age-induced changes (Ford & Timmins, 1989). The 
absence of the drug melting peak in the DSC thermal profile of a solid dispersion 
indicates that the drug is dispersed molecularly, or it exists in the amorphous 
form. Moreover, since polymorphs generally have different melting points, DSC 
can be used to detect polymorphism. This property is extremely important when 
long-chain organic compounds are studied, because nearly all these compounds 
 
9
exhibit polymorphism (Martin et al., 1993). Figure 1.1 shows a diagram of a 
DSC system, and a typical thermal profile of a material that undergoes glass 
transition, recrystallization and meting. 
 
1.1.5(b)   X-ray diffraction 
Diffraction of X-rays is the basic technique for obtaining information on the 
atomic structure of crystalline solids. The phenomenon of X-ray diffraction by 
crystals results from a scattering process in which X-rays are scattered by the 
electrons of the atoms without change in wavelength (Balta-Calleja & Vonk, 
1989). The crystallinity in a sample is reflected by a characteristic fingerprint 
region in the diffraction pattern. In a solid dispersion, the crystallinity in the drug 
can be separately identified from crystallinity in the carrier by using the X-ray 
diffraction. Therefore, it is possible to differentiate between solid dispersions in 
which the drug is molecularly dispersed, and solid dispersions in which the drug 
is present in the crystalline form. However, crystallinities of under 5-10% cannot 
generally be detected with X-ray diffraction (Leuner & Dressman, 2000). 
 
1.1.5(c)   Fourier transformed infrared spectroscopy 
Fourier transformed spectroscopy is widely used because of its rapid providing 
of high resolution spectra with samples in the nanogram range (Ikan & 
Crammer, 1987). Structural changes and lack of crystal structure can lead to 
changes   in  bonding  between  functional  groups  which  can  be  detected  by 
infrared spectroscopy. Since not all peaks in the IR spectrum are sensitive to 
crystalline changes, it is possible to differentiate between those that are 
sensitive to changes in crystallinity and those that are not ( Leuner & Dressman,  
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       Figure 1.1 Diagram of a DSC system (top), Typical thermogram (below). 
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2000; Taylor & Zografi,1997). 
 
1.1.6   Advantages of solid dispersions 
1.1.6(a)   Increased dissolution rate 
The fact that more than 40% of newly discovered drugs have little or negligible 
water solubility presents a serious challenge to the successful development and 
commercialization of new drugs in the pharmaceutical industry (Connors & 
Elder, 2004). Solubility and permeability are the main factors that control oral 
bioavailability of a drug substance. Generally, when the drug solubility in water 
is less than 10 mg/ml, dissolution is the rate-limiting step in the process of drug 
absorption (Habib, 2000).  
 
Factors influencing drug dissolution rate in aqueous solution are described in 
Noyes-Whitney equation: 
 
hCsCADdT
dC /)( 
                         
 
 
where dC/dT is the rate of dissolution, A is the surface area available for 
dissolution, D is the diffusion coefficient of the drug, Cs is the solubility of the 
drug in the dissolution medium, C is the concentration of drug in the medium at 
time t and h is the thickness of the diffusion boundary layer adjacent to the 
surface of the dissolving drug (Leuner & Dressman, 2000). According to this 
equation,  dissolution rate can be increased through increasing the surface 
area, and this can be achieved through  reducing the particle size.  
 
(1.1) 
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Different methods have been used to reduce the particle size, such as 
micronization, recrystallization, freeze drying and spray drying. Micronization of 
poorly soluble drugs by milling has been used for many years in the 
pharmaceutical industry in order to enhance the dissolution rate of those drugs. For 
example the dissolution rate of  micronized spironolactone was higher than that of 
the standard form (McInnes et al., 1982). However, fine particles may not always 
produce the expected faster dissolution. This primarily results from the aggregation 
and agglomeration of fine particles. In addition, poor wettability of fine powders 
may reduce the dissolution rate (Bloch & Speiser, 1987; Rippie, 1986). 
  
Solid dispersion techniques have been used to enhance the dissolution rate of 
many poorly water soluble drugs. Particle size reduction and reduced 
agglomeration would both increase the exposed surface area of the drug. When 
solid solutions or amorphous precipitations are formed, particle size of the 
active ingredient is reduced to the minimum level. In addition, the carrier 
material may contribute to increasing the dissolution rate through its solubilizing 
and wettability-enhancing  properties. It was reported that urea increased the 
dissolution rate of chlorpropamide incorporated into urea, through its solubilizing 
properties (Ford & Rubenstein, 1977). The enhancement in dissolution rate as a 
result of solid dispersion formation, relative to pure drug, varies from as high as 
400-fold to less than two-fold (Vadnere, 2002). 
 
1.1.6(b)   Enhanced oral bioavailability 
Drug dissolution is a prerequisite to drug absorption and in vivo effectiveness 
for almost all drugs given orally (Antal, 2001). This can be explained by Fick’s 
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first law which describes the diffusion of a substance through a membrane: 
dx
dcDAdt
dm   
where dm/dt is the diffusion rate, D is the diffusion constant, A is the membrane 
surface area, dc is the change in concentration, and dx is the membrane 
thickness. From this law, it can be inferred that the drug flux through the 
intestinal wall, during the diffusion process, is directly proportional to the 
concentration gradient between drug in the gut and drug in the blood 
(Stavchansky & McGinity, 1990). This may explain why poorly soluble drugs are 
represented very often by low absorption and poor bioavailability (Bloch & 
Speiser, 1987). Many studies indicated that increased dissolution rate of poorly 
soluble drugs, from their solid dispersions, led to an improvement in the oral 
bioavailability of those drugs. Examples include, but not limited to, phenytoin 
dispersions in polyethylene glycol 4000 (PEG 4000) (Yakou  et al., 1984), 
nitrofurantoin dispersions in polyethylene glycol 6000 (PEG 6000), 
polyvinylpyrrolidone (PVP) and mannitol (Ali & Gorashi, 1984), digitoxin 
dispersions in deoxycholic acid (Reddy et al., 1976), tolbutamide dispersions in 
polyvinylpyrrolidone (PVP) (Sekikawa et al., 1979), sulfamethoxazole dispersions 
in polyvinylpyrrolidone (PVP) (Sekikawa et al., 1982) and dicumarol dispersions 
in polyvinylpyrrolidone (PVP) (Sekikawa et al., 1983). The aforementioned 
examples, and many others, show the importance of solid dispersion techniques 
as a mean of increasing the oral bioavailability of poorly water-soluble drugs. 
Moreover, the enhanced bioavailability of some drugs, formulated in solid 
dispersions, has led to a reduction in the therapeutic dose of those drugs. For 
example the dose of reserpine, dispersed in polyvinylpyrrolidone (PVP), was 
reduced to one third of its usual value (Stupak & Bates, 1972); similarly, the dose 
(1.2) 
 
14
of griseofulvin, dispersed in polyethylene glycol (PEG), was reduced from 500 mg 
to 250 mg (Barrett & Bianchine, 1975). 
 
1.1.7   Limitations of solid dispersions 
 
Despite an active research interest, the commercial application of solid dispersion 
in dosage form design has been very limited. Only two products, griseofulvin in 
polyethylene glycol and nabilone in polyvinylpyrrolidone solid dispersions, were 
marketed during the three decades following the initial work of Sekiguchi and Obi 
in 1961 (Serajuddin,1999).  
 
Main problems limiting the commercial application of solid dispersion involve (a) 
the physical and chemical stability of drugs and vehicles, (b) method of 
preparation,  (c) reproducibility of its physicochemical properties,  (d) its 
formulation into dosage forms, and (e) the scale-up of manufacturing processes. 
 
1.1.7(a)   Stability  
Physical instability of solid dispersions such as phase separation and subsequent 
crystallization may reduce the dissolution rate of the active ingredients. Since 
many solid dispersions contain amorphous or molecularly dispersed drugs, they 
are often susceptible to crystallization during storage (Ford, 1986). Similarly, 
certain carriers may exist in thermodynamically unstable states in solid 
dispersions and undergo changes with time (Serajuddin, 1999). Andronis et al. 
(1997) reported that moisture might facilitate the crystallization of amorphous 
drugs, and for this reason solid dispersions should be protected from moisture. 
Various studies reported reduced dissolution rates of drugs, incorporated into solid 
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dispersions, upon ageing. Solid dispersion systems such as chlorpropamide-urea, 
indomethacin-polyethylene glycol 6000,  and phenylbutazone-polyethylene glycol 
6000 showed reduced dissolution rates of active ingredients on storage (Ford & 
Rubinstein, 1981; Ford & Rubinstein 1979; Khalil & Mortada, 1978). 
 
1.1.7(b)   Method of preparation 
When fusion method is used, high melting temperature may chemically 
decompose drugs and/or carriers. On the other hand, total removal of toxic 
organic solvents used in the preparation of the dispersions is the main problem 
associated with the solvent method.  Hence, the extrusion method provides a 
good alternative to the fusion and solvent methods. 
 
1.1.7(c)   Reproducibility of physicochemical properties 
Manufacturing conditions may greatly influence the physicochemical properties 
of solid dispersions (Franco et al., 2001). Various investigators observed that 
heating rate, maximum temperature used, holding time at a high temperature, 
cooling method and rate and method of pulverization might affect the properties 
of solid dispersions prepared by the melting method including the particle size 
distribution. In addition, the nature of solvent used, ratio of drug/solvent or 
carrier/solvent, as well as the rate and method used to evaporate the solvent 
may significantly influence the physicochemical properties of solid dispersions 
formed (Serajuddin, 1999). 
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1.1.7(d) Dosage form development 
Pulverizing, sieving, mixing and compressing of solid dispersions, which are 
usually soft and tacky, are difficult. This may reduce the chance of developing 
suitable solid dosage forms of drugs dispersed in solid dispersions. 
 
1.1.7(e) Scale-up of manufacturing processes 
The physicochemical properties and stability of solid dispersions may be 
affected by scale-up processes because heating and cooling rates of solid 
dispersion prepared in a large scale may differ from that of a small scale. It is 
also expensive and not practical to evaporate hundreds and even thousands of 
liters of organic solvents to prepare solid dispersions for kilogram quantities of 
drugs (Serajuddin, 1999). 
 
1.2   Gelucires 
1.2.1  Definition 
The utility of lipid-based oral formulations has been recognized for many years 
(Porter & Charman, 2001). Gelucires are a family of lipid-based excipients 
comprising glycerides and esters of polyethylene glycol (PEG), these two 
components conferring hydrophobic and hydrophilic properties to the vehicle. 
Each Gelucire is characterized by two numbers, the first referring to the nominal 
melting point of the base and the second to the HLB value (Craig, 1995). 
Gelucires come in a variety of grades with different melting points (from 33 ºC to 
65 ºC) and HLB values (from 1 to 14). Gelucires are described under lauroyl 
macrogolglycerides monograph in the British Pharmacopoeia (BP, 2005).   
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1.2.2  Pharmaceutical applications of Gelucires 
The wide range of materials within the Gelucires group results in a wide range 
of properties, particularly in terms of melting/crystallization behavior and 
hydrophobicity. Consequently, it is possible to choose the Gelucire according to 
the particular formulation requirement, either in terms of manufacturing method 
or the rate of drug release (Craig, 1995). Different rates of drug release can be 
obtained by mixing the same active substance with Gelucires of different 
melting points and HLB values (Howard & Gould, 1987). Table 1.2 shows 
different applications of different Gelucires. 
 
                    Table 1.2 Pharmaceutical uses of some Gelucires.   
Types of gelucires Uses 
Gelucire 33/01, Gelucire 39/01, Gelucire 43/01 Vehicle, oily phase for ointment. 
Gelucire 44/14 
Emulsifier for solid and semi solid 
self-microremulsifying drug 
delivery systems, bioavailability 
enhancer. 
Gelucire 50/13, Gelucire 53/10 Hydrophilic glyceride for semi-solid formulations. 
Gelucire 50/02, Gelucire 50/13, Gelucire 
54/02, Gelucire 70/02 
Coating and matrix agents for 
sustained release formulations. 
 
 
1.2.3  Gelucire 44/14 
Gelucire 44/14 is an inert semi-solid waxy material, which is amphiphilic in 
nature. It has unique emulsifying properties that make it ideal for prompt release 
formulations. The suffixes 44 and 14 refer to its  nominal melting point and HLB 
value respectively. 
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1.2.3(a) Chemical composition 
Gelucire 44/14 is prepared from the reaction of hydrogenated palm kernel oil 
with polyethylene glycol 1500 (PEG 1500). Its composition is approximately:                    
 20% mono-, di- and triglycerides, 
 72% mono- and di- fatty acids esters of PEG 1500, 
 8% free PEG 1500. 
Table 1.3 shows the fatty acid distribution in Gelucire 44/14. 
 
Table 1.3 Fatty acid distribution in Gelucire 44/14 (Gattefossè, 2001) 
Caprylic 
acid 
C8 
Capric  
Acid 
C10 
Lauric  
acid 
C12 
Myristic 
acid 
     C14 
Palmitic 
acid 
C16 
Stearic  
Acid 
C18 
410% 39% 4050% 1424% 414% 515% 
 
Because of its unique balance of short, medium and long chain fatty acids, 
Gelucire 44/14 forms an exceptionally stable fine dispersion when in contact 
with the gastrointestinal fluids (Roussin & Laforet, 1997).  
 
1.2.3(b) Pharmaceutical applications of Gelucire 44/14 
Numerous drugs have been formulated with Gelucire 44/14. Solubilization 
properties and low melting point of Gelucire 44/14 make it a suitable carrier for 
many poorly watersoluble drugs.  Drugs dispersed in Gelucire 44/14, alone 
or in a mixture with other excipients, showed enhanced solubility and 
dissolution, for example, UC781 (thiocarboxanilide derivative) (Damian et al., 
2000), DMP 323 (protease inhibitor drug) (Aungst et al., 1997), REV 5901 (5-
lipoxygenase inhibitor) (Serajuddin et al., 1988), temazepam and triamterene 
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(Dordunoo et al., 1991). Moreover, improved oral bioavailability of drugs 
dispersed in Gelucire 44/14, alone or in a mixture with other excipients, has also 
been reported. Examples include -tocopherol (Barker et al., 2003), 
albendazole (Savio et al., 1998), REV 5901 (Sheen et al., 1991), piroxicam 
(Yuksel et al., 2003), halofantrine (Khoo et al., 2000), PG301029 (antiviral 
agent) (He et al., 2005) and flurbiprofen (Soliman & Khan, 2005).  
 
Reduced drug particle size, increased wettability of drug particles, emulsifying 
properties of the carrier, lymphatic drug transportation and enhanced drug 
permeability are among the proposed mechanisms underlying the improved 
bioavailability of drugs dispersed in Gelucire 44/14 (Serajuddin et al., 1988; 
Hauss et al.,1998; Saha & Kou, 2000).  
 
1.3 Fenofibrate 
1.3.1   Introduction 
Fibric acid derivatives (fibrates) play an important role in the management of 
hyperlipidemia. Indeed, they are among the most effective agents available for 
lowering serum triglycerides (Penn et al., 2006). Clofibrate, the first member of 
this group, was described in 1962. Subsequently, gemfibrozil, fenofibrate, 
bezafibrate and ciprofibrate were introduced.  Fenofibrate was launched in 1975 
in a conventional formulation; while micronized and supra-bioavailable 
formulations were developed in 1990 and 2001 respectively.  
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1.3.2   Description 
Fenofibrate, 2 - [4 - (4 - chlorobenzoyl) phenoxy] - 2 - methyl - propanoic acid  
1-methyethylester, has a molecular weight of 360.84 and it is hydrophobic in 
nature (log P=5.24). Having low solubility and high permeability, fenofibrate is 
considered as a Class II drug according to the Biopharmaceutics Classification 
System (Granero et al., 2005). Fenofibrate exists in the form of white or almost 
white, crystalline powder. It is practically insoluble in water, very soluble in 
methylene chloride and slightly soluble in alcohol (BP, 2005). It has a melting 
point of 79-82 ºC. Figure 1.2 shows the chemical structure of fenofibrate and 
fenofibric acid. 
      
          Figure 1.2 The chemical structure of fenofibrate and fenofibric acid. 
 
1.3.3   Clinical pharmacology 
The lipid-modifying effects of fenofibric acid, the active metabolite of fenofibrate, 
are characterized by a reduction in low density lipoprotein cholesterol (LDL-C) 
and total cholesterol (TC) levels, a marked reduction in plasma triglycerides 
(TG) levels and an increase in high density lipoprotein cholesterol (HDL-C) 
levels (Adkins & Faulds, 1997). Fenofibric acid appears to have a wide range of 
effects on the synthetic and catabolic pathways of cholesterol and triglyceride 
metabolism (Najib, 2002).  
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Fenofibric acid is a potent synthetic activator of the peroxisome proliferator-
activated receptor alpha  (PPARα) and it is believed that most of its effects are 
mediated by this receptor. Activation of PPARα increases the ratio of apoprotein 
apo C-II, an activator of lipoprotein lipase, to apoprotein apo C-III, an inhibitor of 
lipoprotein lipase. As a result, lipolysis and elimination of triglyceride-rich 
particles from plasma is increased. In addition, activating PPARα induces an 
increase in the expression of apolipoprotein-AI and apolipoprotein-AII, which 
are the major protein constituents of HDL-C. This may explain the mechanism 
by which fenofibric acid increases  the HDL-C levels (Kersten et al., 2000; 
Mahley & Bersot, 2001).  
 
Potential beneficial nonlipid effects of fenofibric acid include reductions in 
spontaneous platelet aggregation and plasma fibrinogen, and a reduction in 
serum uric acid levels (Balfour et al, 1990; Guay, 1999). 
  
1.3.4 Pharmacokinetic properties 
Fenofibrate is a prodrug, which after absorption is hydrolyzed to its active 
metabolite, fenofibric acid (Balfour et al., 1990). A study using radiolabeled 
fenofibrate showed that only fenofibric acid was found in the plasma and no 
unchanged fenofibrate could be detected (Benedetti et al., 1986). Fenofibric 
acid is extensively bound to plasma albumin (~99%), The plasma half-life is 
about 20 hours, which allows a once daily dosage regimen (Adkins & Faulds, 
1997). Fenofibric acid is excreted predominantly in the urine, mainly as the 
glucuronide conjugate, but also as a reduced form of fenofibric acid and its 
glucoronides. Based on urinary excretion data, oral bioavailability of standard 
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fenofibrate, under fasting conditions, was estimated to be 30% (Desager & 
Harvengt, 1978). However, taking fenofibrate in its standard formulation during 
a meal increases its oral bioavailability to 60% (Munoz et al., 1994). 
 
1.3.5   Fenofibrate formulations with enhanced bioavailability 
Since the aqueous solubility of fenofibrate is less than 0.5 mg/l (Law et al., 2003), 
its dissolution may represent the rate-limiting step in the oral absorption of the 
drug. Conventional formulations that incorporate unmilled or non-micronized forms 
of fenofibrate have incomplete or slow dissolution. Furthermore, these conventional 
formulations exhibit low and/or variable oral bioavailability. One approach in 
producing pharmaceutically acceptable fenofibrate formulations involves the use of 
micronization technique. U.S. Pat. No. 4,895,726 (Curtet et al., 1990) disclosed a 
method of improving the dissolution, and consequently, the bioavailability of 
fenofibrate. According to this patent, fenofibrate powder is co-micronized with a 
solid wetting agent. Sodium lauryl sulfate is described as the solid wetting agent of 
choice. The bioavailability of fenofibrate was significantly improved over the non-
micronized form.  Moreover, it was found that 67 mg of the new formulation gave 
the same absorbed amount as did 100 mg of the conventional formulation. As a 
result, the daily dose of fenofibrate was reduced from 300 mg, of the standard 
form, to 200 mg of the micronized form (Guichard & Sauron, 1993). 
 
In another attempt to increase fenofibrate oral bioavailability, a suprabioavailable 
formulation was developed and introduced to the market in 2001. The formulation 
combines the micronization technology with a new micro-coating process. The 
formulation is prepared by coating micronized fenofibrate particles directly onto an 
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inert excipient core (Figure 1.3). As a result, the micronized fenofibrate particles 
are immediately exposed to the dissolution medium and a significant increase of 
the dissolution rate from the tablet is obtained. By using this technique, the oral 
bioavailability of fenofibrate could be increased by 25%. Therefore, a dose of 
160 mg of the new suprabioavailable tablet is sufficient to give plasma levels 
equivalent to those previously achieved by a dose of 200 mg of the micronized 
fenofibrate capsule (Guichard et al., 2000).  
 
 
 
 
 
 
                            
                     Figure 1.3 Fenofibrate suprabioavailable formulation 
 
1.4   Summary and scope of the study 
Solid dispersions provide a simple and effective method of increasing 
solubility and oral bioavailability of poorly water-soluble drugs. More 
specifically, solid dispersions prepared with  self-emulsifying carriers, such 
as Gelucire 44/14, are of a special interest due to their unique properties. 
Hence, the present study was carried out to investigate the utility of Gelucire 
44/14 for formulating solid dispersions of fenofibrate with aim of enhancing 
its oral bioavailability. Previous techniques used to improve the oral 
bioavailability of fenofibrate, such as co-micronization and microcoating, are 
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time-consuming and/or costly. Simple melt-fusion technique, as employed in 
this study, offers a more economical means of producing fenofibrate, with 
enhanced oral bioavailability, in a solid dispersion dosage form. 
 
This study was conducted in stages with the following objectives: 
1. To prepare and characterize fenofibrate-Gelucire 44/14 solid dispersions. 
2. To develop a new formulation of fenofibrate with increased dissolution rate. 
3. To develop a simple HPLC method for analysing fenofibric acid in plasma. 
4. To compare the oral bioavailability of fenofibrate in the developed formulation       
5.  with that of micronized fenofibrate.                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
